



Dr. Reddy's Laboratories Announces Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB

Torreya advised Dr. Reddy's on the transaction

Hyderabad, India & Princeton, NJ, August 9, 2021

Dr. Reddy's Laboratories Limited (Dr. Reddy's) announced that it has entered into a definitive asset purchase agreement to sell its US and Canada territory rights for ELYXYB to BioDelivery Sciences International (BDSI). ELYXYB, previously known as DFN-15, is indicated for the acute treatment of migraine with or without aura in adults.

Under the terms of agreement, Dr.Reddy's will receive \$6 million upfront upon closing followed by \$9 million on August 3, 2022. Further, Dr. Reddy's is eligible to receive event-based, sales-based milestones and quarterly earn-out payments. The closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.

Torreya advised Dr. Reddy's on this transaction, which reinforces Torreya's strength and leadership position as an advisor to specialty pharmaceutical companies. Torreya has advised on over 20 assignments to date in 2021.

ABOUT DR. REDDY'S LABORATORIES LIMITED:

For more information about Dr. Reddy's, please see: www.drreddys.com

ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.:

For more information about BDSI, please see: www.bdsi.com

Deal Press Release

Torreya Contact

NITIN LATH

Managing Director | Mumbai Office

nitin.lath@torreya.com | +91 22-6127-1191 | [BIO](#)

LESLIE GAUTAM

Executive Director | New York Office

leslie.gautam@torreya.com | 212.257.5816 | [BIO](#)

Dr.Reddy's 

Sale of U.S. and Canadian
rights for ELYXYB to



\$6 million + milestones

August 2021
Announced

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.